Dexcom Further Advances Vision of Glucose Biosensing for All

Key Terms

glucose biosensing medical

Glucose biosensing is the use of a biological or chemical sensor to detect and measure blood sugar levels, typically through a small device or patch that reads body fluids and converts that signal into a readable number. Investors care because these sensors can drive steady revenue from devices and consumables, change how chronic diseases are managed, and face regulatory and adoption hurdles similar to launching a new consumer gadget — think of it as a reliable meter that tells you how your body’s fuel is behaving.

glucose biosensor medical

A glucose biosensor is a medical device that measures the amount of sugar in a small blood or interstitial fluid sample and displays a numerical reading, like a fuel gauge for the body’s glucose level. Investors care because these sensors drive recurring sales (sensors, test strips, reader devices), influence healthcare costs and patient outcomes, and face regulatory approval and reimbursement decisions that directly affect a company’s revenue and growth prospects.

type 2 diabetes medical

Type 2 diabetes is a chronic condition where the body struggles to control blood sugar levels because it becomes less responsive to insulin, a hormone that helps regulate sugar in the blood. It matters to investors because it can lead to increased healthcare costs, affect workforce productivity, and influence the performance of companies in the healthcare and pharmaceutical sectors. Managing or preventing the condition has significant implications for public health and economic stability.

metabolic syndrome medical

A cluster of common health problems—usually high blood pressure, high blood sugar, excess belly fat, and abnormal blood fats—that often occur together and raise the risk of heart disease, stroke and diabetes. Think of it like a car dashboard with several warning lights on at once: because the issues reinforce each other, they lead to bigger long-term healthcare needs and spending. Investors care because it drives demand for drugs, devices, diagnostics, chronic-care services and workplace health programs, shaping market size and regulatory attention.

fda clearance regulatory

FDA clearance is the U.S. Food and Drug Administration’s official permission to market certain medical devices or diagnostic tests after reviewing evidence that they are as safe and effective as similar products already on the market. For investors, it’s like a product passing a required safety inspection — it reduces regulatory uncertainty, speeds commercial rollout, and can directly affect sales prospects, valuation, and partnership opportunities.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

• At Aspen Ideas: Health, Dexcom announced regulatory milestones, including pediatric clearance for Stelo, further advancing access to glucose biosensing in the United States.
• The company also announced details regarding the rollout of its fully reimagined Stelo app experience launching in July in the US, helping make glucose insights more approachable and actionable for people seeking better health.
• Expanded international availability of Stelo is also planned for the United Kingdom, Australia, New Zealand and South Korea starting later this year and will continue into 2027.

At Aspen Ideas: Health, Dexcom announced regulatory milestones, including pediatric clearance for Stelo, further advancing access to glucose biosensing in the United States.

“Glucose matters for everyone and better understanding it can help prevent serious health complications,” said Jake Leach, president and CEO of Dexcom. “That’s why we’re working to expand access to glucose biosensing to make preventive, personalized care a reality and making our Stelo app experience more approachable with real-time insights that help people act earlier, before disease takes hold."

The importance of glucose awareness and expanding access to biosensing technology will be the focus of a discussion today at Aspen Ideas: Health, where Leach will join biochemist and New York Times bestselling author Jessie Inchauspé (Glucose Goddess) and moderator Ami B. Bhatt, MD, FACC, and chief innovation officer of the American College of Cardiology. Together, they will explore the role of glucose in overall health, the promise of personalized preventive care, and the continued systemic changes needed to ensure innovative biosensing technologies are available to more people.

Stelo receives clearance for expanded indication for pediatric use

Earlier this month, Stelo received FDA clearance expanding its indication for use from adults ages 18 and older not using insulin to now include children ages 2 years and older not using insulin. This milestone expands access to glucose insights for millions of families at a time when youth onset Type 2 diabetes continues to rise and metabolic syndrome has become increasingly prevalent among 4.5% of youth younger than 18 years old in the United States.¹ According to the Centers for Disease Control and Prevention (CDC), the prevalence of Type 2 diabetes among children has increased significantly over the last 20 years, and projections suggest cases could continue to increase by 700%.²

By bringing the convenience and accessibility of a glucose biosensor without a prescription to children and adolescents not using insulin, Stelo has the potential to empower pediatric users, along with their caregivers, with valuable glucose data that can support healthier lifestyle choices and foster greater awareness of metabolic health earlier in life.

Dexcom will begin the rollout of its reimagined Stelo app experience starting in July with future plans for global expansion

As healthcare begins to shift toward prevention and personalization, Dexcom believes glucose biosensing can play a critical role in helping people better understand how everyday choices impact their health. The reimagined Stelo experience is designed to make glucose insights easier to understand and act on, helping users build awareness of how food, activity, sleep and stress influence their overall wellbeing.

Dexcom also reiterated today its plans to expand the availability of Stelo internationally, with launches anticipated in the United Kingdom, Australia, New Zealand and South Korea beginning later this year and continuing into 2027, expanding access to glucose biosensing and metabolic health insights to more people globally.

To learn more about Stelo or to purchase, visit Stelo.com or Amazon. To learn more about the portfolio of Dexcom glucose biosensors, visit Dexcom.com.

About Dexcom

Dexcom empowers people to take control of health through innovative biosensing technology. Founded in 1999, Dexcom has pioneered and set the standard in glucose biosensing for more than 25 years. Its technology has transformed how people manage diabetes and track their glucose, helping them feel more in control and live more confidently.

Dexcom. Discover what you’re made of. For more information, visit Dexcom.com.

Category: IR

<sup>1. Wilson, DP; Shah, AS. Journal of Clinical Lipidology. (2025). 19(4):4-14.
2. Center for Disease Control and Prevention: Diabetes in Young People Is on the Rise (2024)</sup>

View source version on businesswire.com: https://www.businesswire.com/news/home/20260623413946/en/

Media Contact
James McIntosh
mediarelations@dexcom.com

Investor Contact
Sean Christensen
sean.christensen@dexcom.com

Source: DexCom, Inc.